Belgium· BE-AMP-SAM526702-00

Fotivda 890 µg

A tivozanib product containing tivozanib hydrochloride monohydrate, registered in Belgium by Recordati Netherlands. The same ATC class is registered in 10 of our 19 countries.

ATC L01EK03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedFotivda 890 µgATCL01EK03REGISTER NO.BE-AMP-SAM526702-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Tivozanib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EK03 (tivozanib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Tivozanib · ATC L01EK03

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Tivozanib Hydrochloride Monohydrate
Manufacturer
Recordati Netherlands
Country
Belgium (BE)
ATC code
L01EK03
ATC class
Tivozanib
Defined daily dose
1 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for tivozanib.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tivozanib · interactions on record

7 records

  • 3 severe
  • 4 moderate

Most severe, free to view

  • PhenobarbitalN03AA02severe
  • PhenobarbitalN05CA24severe
  • Hyperici herbaN06AX25severe
  • RiociguatC02KX05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tivozanib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tivozanib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fotivda
  • Liechtenstein · Fotivda
  • Norway · Fotivda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8d0ad497-4968-486f-9e61-45a72268525e
GET /v1/drugs/8d0ad497-4968-486f-9e61-45a72268525e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Fotivda 890 µg",
  "name_fr": "Fotivda 890 µg",
  "name_nl": "Fotivda 890 µg",
  "amp_code": "SAM526702-00",
  "strengths": [
    "890.0000",
    "890.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Tivozanib Hydrochloride Monohydrate",
    "Tivozanib",
    "E 102",
    "Mannitol",
    "Propylene Glycol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Tivozanib",
  "authorisation_numbers": [
    "EU/1/17/1215/001"
  ]
}

See everything about tivozanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.